Trial · NCT07375654
Combined Use of Cyclosporine and Metformin in Treatment of Psoriasis vs Cyclosporine Alone
NCT07375654, Phase 1, Completed, Cairo University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combined Use of Cyclosporine and Metformin in Treatment of Psoriasis vs Cyclosporine Alone. Trials, record NCT07375654. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07375654
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combined Use of Cyclosporine and Metformin in Treatment of Psoriasis vs Cyclosporine Alone
- NCT number
- NCT07375654
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 32 participants, actual
- Lead sponsor
- Cairo University
- Conditions
- Psoriasis
- Interventions
- Cyclosporin (CSA), Metformin (500 mg Twice a day)
- First posted
- 2026-01-29
- Last updated
- 2026-01-29
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Primary Outcome Measure 1 Change in Psoriasis Area and Severity Index (PASI) | Baseline (Pretreatment) ,Post-treatment(At 3 months),At 6 months | Comparison of PASI scores before and after treatment within each group and between both treatment groups. Unit of Measure: PASI score Scale: 0-72 (higher scores indicate more severe psoriasis) |
| Primary | Primary Outcome Measure 2 Change in Body Surface Area (BSA) | Baseline (pretreatment), 3 months, and 6 months post-treatment | Comparison of the percentage of body surface area affected by psoriasis before and after treatment within each group and between both treatment groups. Unit of Measure: Percentage of body surface area (%) Scale: 0-100% (higher percentages indicate greater skin involvement) |
| Primary | Primary Outcome Measure 3 Change in Dermatology Life Quality Index (DLQI) | Baseline (pretreatment), 3 months, and 6 months post-treatment | Comparison of DLQI scores before and after treatment within each group and between both treatment groups. Unit of Measure: DLQI score Scale: 0-30 (higher scores indicate greater impairment of quality of life) |
| Secondary | Patient satisfaction . | Post treatment(AT 3 months) | Patients' Global Satisfaction Scale ranging from -1 to 3. Patient satisfaction is graded as excellent (3), moderately satisfied (2), poorly satisfied (1), not satisfied (0), or condition worsened (-1), with higher scores indicating greater patient satisfaction and better clinical outcome. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07375654
GET https://conductscience.org/api/trials/v1/NCT07375654/registered